Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11

被引:49
作者
Nakatsu, S
Kondo, S
Kondo, Y
Yin, DL
Peterson, JW
Kaakaji, R
Morimura, T
Kikuchi, H
Takeuchi, J
Barnett, GH
机构
[1] CLEVELAND CLIN FDN,DEPT NEUROSURG,CTR CANC,BRAIN TUMOR CTR,CLEVELAND,OH 44195
[2] KYOTO UNIV,FAC MED,DEPT NEUROSURG,KYOTO 606,JAPAN
[3] NATL UTANO HOSP,DEPT NEUROSURG,KYOTO 616,JAPAN
[4] CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195
关键词
apoptosis; chemotherapy; camptothecin; SN-38; multidrug resistance; glioma;
D O I
10.1007/s002800050592
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overexpression of the multidrug resistance (mdr 1) gene and its product, P-glycoprotein (P-gp), is thought to limit the successful chemotherapy of human tumors. Recent studies demonstrate that SN-38, a metabolite of the camptothecin (CPT) derivative CPT-11, has antitumor effects on several tumors, but the mechanisms responsible for its cytotoxicity remain unclear. We therefore determined whether SN-38 has cytotoxic effects on MDR human glioblastoma GB-1 cells and non-MDR human glioblastoma U87-MG cells. Furthermore, we determined what role SN-38 plays in the induction of cytotoxicity in these tumor cells. In this study, we demonstrated that SN-38 had significantly stronger antirumor effects on GB-1 and U-87MG cells than did CPT (P < 0.01 and P < 0.05, respectively). In addition, findings obtained using a DNA fragmentation assay, Hoechst 33258 staining, in situ end-labeling and cell cycle analysis demonstrated that SN-38 induced apoptosis in these tumors. Our results suggest that SN-38 has a stronger antitumor effect on malignant glioma cells regardless of MDR expression than does CPT, and therefore can be considered a new chemotherapeutic agent potentially effective in the treatment of human primary or recurrent malignant gliomas resistant to chemotherapy.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 46 条
[1]   THE MULTIDRUG RESISTANCE (MDR1) GENE-PRODUCT FUNCTIONS AS AN ATP CHANNEL [J].
ABRAHAM, EH ;
PRAT, AG ;
GERWECK, L ;
SENEVERATNE, T ;
ARCECI, RJ ;
KRAMER, R ;
GUIDOTTI, G ;
CANTIELLO, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :312-316
[2]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[3]   REVERSAL OF MULTIDRUG RESISTANCE [J].
CHABNER, BA ;
WILSON, W .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :4-6
[4]   DEVELOPMENTAL CELL-DEATH - MORPHOLOGICAL DIVERSITY AND MULTIPLE MECHANISMS [J].
CLARKE, PGH .
ANATOMY AND EMBRYOLOGY, 1990, 181 (03) :195-213
[5]  
DELBINO G, 1992, CELL PROLIFERAT, V25, P537
[6]  
DKE DC, 1987, P NATL ACAD SCI USA, V80, P6361
[7]  
EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275
[8]  
GALLO RC, 1971, J NATL CANCER I, V46, P789
[9]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[10]  
GOLDSTEIN LJ, 1991, CONT ONCOL MAY, P38